Content about Thiazoles

January 3, 2013
Experimental ALS drug fails in trial

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

June 28, 2012
Mylan launches thiamine-deficiency drug

Mylan has launched a generic drug for treating thiamine deficiency, the company said Thursday.

PITTSBURGH — Mylan has launched a generic drug for treating thiamine deficiency, the company said Thursday.

The generic drug maker announced the launch of thiamine hydrochloride injection in the 100-mg-per-mL strength, packaged in 25-vial packs of 200-mg-per-2-mL multiple-dose vials.

The drug had sales of about $18.6 million during the 12-month period ended in March, according to IMS Health. Mylan said it would ship the drug immediately.

December 2, 2011
Mylan generic drug for HIV/AIDS receives tentative FDA approval through PEPFAR

Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

PITTSBURGH — Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

The drug maker's Mylan Labs subsidiary received tentative approval for atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength. The FDA's tentative approval of the drug under PEPFAR means it will be eligible for purchase in certain developing countries.

October 11, 2011
Antacids expect some upset

Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


October 20, 2010
Combining Invirase, Norvir could cause health problems

Combining two antiviral drugs for HIV may raise the risks of life-threatening heart problems, the...

July 5, 2010
Lupin gets nod for GERD drug

The Food and Drug Administration has approved a gastroesophageal reflux disease drug made by Lupin...

February 11, 2010
FDA approves new formulation of HIV treatment drug

The Food and Drug Administration has approved a new formulation of an anti-retroviral drug for...

January 10, 2010
New P&G initiative may create clash of the OTC titans

This is shaping up to be a Fight Night dream card, with the battle arena...

WHAT IT MEANS AND WHY IT'S IMPORTANT This is shaping up to be a Fight Night dream card, with the battle arena located in the digestives aisle of a pharmacy near you. Are you ready to rumble?

(THE NEWS: P&G develops new program in line with Prilosec OTC. For the full story, click here)